You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Proscia said that Unilabs will use its suite of artificial intelligence applications to implement computational pathology into routine pathology workflows.
The global distribution deal with Epredia follows Paige's closing of a $125 million round of Series C financing earlier this year.
At ACLA's annual meeting, a panel discussed how machine learning, artificial intelligence, telehealth, and at-home testing have gained traction throughout the laboratory industry.
The companies have agreed to join their respective technologies into an integrated product for artificial intelligence-based prostate cancer diagnosis.
Paige said it will use the financing to expand its geographic footprint as it accelerates the development of artificial intelligence-based clinical applications, biomarkers, and diagnostic tests.
The company said it will use the funding to continue development of its computational technologies, biomarkers, and diagnostics, as well as for new hires.
The firm said that its AI-based breast cancer detection software, Paige Breast, draws a pathologist's attention to concerning features on a breast tissue slide.
Scale Venture Partners led the Series B round with participation from Hitachi Ventures. Proscia raised $8.3 million in its Series A round in 2018.
Hologic designed its scalable AI-based cytology platform to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
The deal provides clinicians with digital access to Flagship Bio's TissueInsight via Inspirata's Dynamyx digital pathology product.